5 Best Genomic Stocks to Buy Now

Page 1 of 5

Below you can find the list of 5 best genomic stocks to buy now according to hedge funds. For a detailed discussion as well as a more comprehensive list please see 12 Best Genomic Stocks To Buy Now.

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, lithium mining is one of the fastest growing industries right now, so we are checking out stock pitches like this emerging lithium stock. We go through lists like the 10 best hydrogen fuel cell stocks to pick the next Tesla that will deliver a 10x return. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our homepage. Keeping this in mind let’s take a look at the best genomic stocks to buy:

5. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

No of HFs: 35

Total Value of HF Holdings: $902 Million

Alnylam Pharmaceuticals, Inc. is ranked as the fifth-best genomic stock to buy now. The company is a biopharmaceutical company that focuses on the production and development of RNA interference therapeutics for genetically defined diseases.

Recently, the company announced the appointment of Tolga Tanguler formed Senior Vice President of Alexion as their Chief Commercial Officer where he will be leading the global marketing, sales, market access, commercial operations, and strategy for the company. John Maraganore, Ph.D., Chief Executive Officer of Alnylam mentioned,

“After an in-depth and comprehensive search, we have selected Tolga Tanguler, a dynamic and highly skilled commercial leader to join Alnylam. With over 20 years of global pharmaceutical and biotech experience, most recently at Pfizer and Alexion, Tolga’s considerable success commercializing multiple rare, specialty and common disease products positions him as an excellent choice for this key role. With Tolga, Kasha, Salil and Aggie joining Alnylam, we have now rounded out our world-class leadership team across our commercial, medical and compliance expertise areas. Together, these outstanding leaders stand poised to support the ongoing global launches of our three marketed products and promising pipeline of innovative medicines addressing a range of patient needs, while we continue on our path towards profitability.”

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)


Page 1 of 5